Abstract
The aim of the present investigation was to study the efficacy and safety of famotidine (MK-208). a new. potent, histamine H2 receptor antagonist, in promoting the healing of active gastric ulcer when compared to placebo. Of the 71 patients who took part in this multicenter double-blind study in Italy. 37 were administered famotidine 40 mg once daily and 34 placebo. Treatment duration was for up to 8 weeks, and endoscopic and clinical studies were performed at onset and week 4 and, if necessary, at weeks 6 and 8. All patients were carefully evaluated at regular intervals for adverse drug reactions by clinical and laboratory examinations. By the end of the study, 97% of the ulcers were healed in the famotidine group compared to 66% in the placebo group (p
Original language | English |
---|---|
Pages (from-to) | 38-44 |
Number of pages | 7 |
Journal | Digestion |
Volume | 32 |
DOIs | |
Publication status | Published - 1985 |
Keywords
- Famotidine
- Gastric ulcer
- Placebo
ASJC Scopus subject areas
- Gastroenterology